We are here to identify your first hit molecules

Using Aurlide’s proprietary technology for vHTS, the hit rate for identifying the first-in-class molecule is very high. Thus far, our team has identified first-in-class molecules for nearly 20 target proteins.

We are here to expand your hit space with new chemical structures and their derivatives

Using our in-house technology, we can incorporate your existing hits and inactive molecules into our vHTS model, which again provides both new types of structural solutions to your hit space, and we can enlarge all hits to a series of compounds.

Using Aurlide’s technology for hit space expansion, the hit-to-lead optimization is practically done, and the optimization of hit molecules, including core hopping, to novel high-affinity ligands can be applied quickly, thus saving both time and money in progress to clinical phases.

We are here to optimize your hits to lead compounds

The hit-to-lead process can be quickly applied with the seamless collaboration between our experts and your medicinal chemistry team.

We are here to help you to choose the most suitable species

Simultaneous optimization of binding into proteins from human and other wished species. By using Aurlide’s discovery platform, it is possible to optimize molecules to bind both to protein in the intended target species and species used in animal tests. This way, we can significantly lower the risk for failures at the pre-clinical phase.

We are here to help you — Contact us »